Related Experiment Videos
Anticoagulation in patients with valvular heart disease, atrial fibrillation, or both
S L Kadish1, E J Lazar, W H Frishman
1Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.
Insights
Anticoagulant drugs like warfarin and heparin are crucial for cardiovascular conditions such as valvular heart disease and atrial fibrillation. This review clarifies their pharmacology and clinical use, addressing ongoing controversies in patient treatment.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Anticoagulant therapies have been available for decades.
- Controversies persist regarding their optimal use in cardiovascular diseases.
Purpose of the Study:
- To review the pharmacology of warfarin and heparin.
- To discuss the clinical applications of these anticoagulants.
- To address controversies in managing patients with valvular heart disease and atrial fibrillation.
Main Methods:
- Review of existing literature on warfarin and heparin.
- Analysis of clinical guidelines and evidence.
Main Results:
- Detailed pharmacology of warfarin and heparin presented.
- Clinical applications in valvular heart disease and atrial fibrillation discussed.
- Current controversies and areas of debate highlighted.
Conclusions:
- Understanding pharmacology is key to appropriate clinical application.
- Evidence-based use of anticoagulants can mitigate risks and improve outcomes.
- Further research may resolve current therapeutic controversies.
Abstract:
Despite the availability of anticoagulant drugs for many years, there are still controversies regarding their use in many cardiovascular conditions. In this article, the pharmacology of warfarin and heparin are reviewed, and the clinical applications of these therapies in patients with valvular heart disease, atrial fibrillation, or both, discussed.